Jacobs Levy Equity Management
ATRA icon

Jacobs Levy Equity Management’s Atara Biotherapeutics ATRA Stock Holding History

Jacobs Levy Equity Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-31,239
Closed -$400K – 940
2023
Q4 		$400K Buy
31,239
+8,563
+38% +$200K ﹤0.01% 858
2023
Q3 		$839K Buy
22,676
+21,999
+3,249% +$979K 0.01% 701
2023
Q2 		$27.3K Sell
677
-25,517
-97% -$1.44M ﹤0.01% 955
2023
Q1 		$1.9M Sell
26,194
-12,337
-32% -$1.2M 0.01% 584
2022
Q4 		$3.16M Buy
38,531
+24,318
+171% +$2.53M 0.02% 472
2022
Q3 		$1.34M Buy
+14,213
New +$1.6M 0.01% 644
2021
Q3 		– Sell
-4,669
Closed -$1.81M – 1035
2021
Q2 		$1.81M Buy
4,669
+1,918
+70% +$684K 0.01% 617
2021
Q1 		$988K Buy
+2,751
New +$1.22M 0.01% 741
2020
Q4 		– Sell
-4,702
Closed -$1.52M – 1014
2020
Q3 		$1.52M Sell
4,702
-430
-8% -$146K 0.02% 569
2020
Q2 		$1.87M Buy
5,132
+4,638
+939% +$1.17M 0.02% 546
2020
Q1 		$105K Sell
494
-829
-63% -$263K ﹤0.01% 958
2019
Q4 		$545K Buy
+1,323
New +$456K 0.01% 774

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Jacobs Levy Equity Management's ATRA Position: Q1 2024 in Review

Jacobs Levy Equity Management sold out of Atara Biotherapeutics (ATRA) in Q1 2024, closing a stake of 31,239 shares — an estimated $400K sold.

Jacobs Levy Equity Management first reported a position in ATRA in Q4 2019 and held it in 12 quarters. The position peaked at $3.16M in Q4 2022. 82 funds tracked by Wall St. Rank hold ATRA as of Q1 2024.

  • Jacobs Levy Equity Management reported no remaining Atara Biotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 31,239 Atara Biotherapeutics shares in Q1 2024, an estimated $400K.
  • Jacobs Levy Equity Management first reported a position in Atara Biotherapeutics in Q4 2019 and held it in 12 quarters.
  • Jacobs Levy Equity Management's Atara Biotherapeutics position peaked at $3.16M in Q4 2022.
  • 82 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2024, filed 15 May 2024.